tbuckley/cabot-search huggingface dataset:
Childhood Cancer and the Risk of ESKD
Authors: Ronit Calderon-Margalit, Oren Pleniceanu, Dorit Tzur, Michal Stern-Zimmer, Arnon Afek, Tomer Erlich, Guy Verhovsky, Lital Keinan-Boker, Karl Skorecki, Gilad Twig, Asaf Vivante
Journal: Journal of the American Society of Nephrology (2020)

Increasing cancer incidence among children alongside improved treatments has resulted in a growing number of pediatric cancer survivors. Despite childhood cancer survivors' exposure to various factors that compromise kidney function, few studies have investigated the association between childhood cancer and future kidney disease.To assess the risk of ESKD among childhood cancer survivors, we conducted a nationwide, population-based, retrospective cohort study that encompassed all Israeli adolescents evaluated for mandatory military service from 1967 to 1997. After obtaining detailed histories, we divided the cohort into three groups: participants without a history of tumors, those with a history of a benign tumor (nonmalignant tumor with functional impairment), and those with a history of malignancy (excluding kidney cancer). This database was linked to the Israeli ESKD registry to identify incident ESKD cases. We used Cox proportional hazards models to estimate the hazard ratio (HR) of ESKD.Of the 1,468,600 participants in the cohort, 1,444,345 had no history of tumors, 23,282 had a history of a benign tumor, and 973 had a history of malignancy. During a mean follow-up of 30.3 years, 2416 (0.2%) participants without a history of tumors developed ESKD. Although a history of benign tumors was not associated with an increased ESKD risk, participants with a history of malignancy exhibited a substantially elevated risk for ESKD compared with participants lacking a history of tumors, after controlling for age, sex, enrollment period, and paternal origin (adjusted HR, 3.2; 95% confidence interval, 1.3 to 7.7).Childhood cancer is associated with an increased risk for ESKD, suggesting the need for tighter and longer nephrological follow-up.
From the President
Authors: Gen Kanayama, James I. Hudson, Harrison G. Pope Jr., Misari Oe, Ulrich Schnyder, Sonja Schumacher, Christoph Mueller-Pfeiffer, Frank H. Wilhelm, Nilüfer Kalebasi, Daniel Roos, Martin Hersberger, Chantal Martin-Soelch, Maurizio Fava, David Mischoulon, Dan Iosifescu, Janet Witte, Michael Pencina, Martina Flynn, Linda Harper, Michael Levy, Karl Rickels, Mark Pollack, Martin Franklin, Edna B. Foa, Helen Blair Simpson, Michael J. Maher, John S. Ogrodniczuk, Carlos Sierra Hernandez, Ingrid Sochting, Anthony S. Joyce, William E. Piper, M.E. Beutel, J. Wiltink, Y. Till, P.S. Wild, T. Münzel, F.M. Ojeda, T. Zeller, R.B. Schnabel, K. Lackner, M. Blettner, I. Zwiener, M. Michal, Anna Ogliari, Marco Battaglia, Elizabeth Maloney, Jin-Mann S. Lin, Christine Heim, William C. Reeves, Urs M. Nater, Zoltan Kozinszky, Robert B. Dudas, Iván Devosa, Sarolta Csatordai, Éva Tóth, Dávid Szabó, János Sikovanyecz, Katalin Barabás, Attila Pál, Elena Tomba, A.M.M. De Vries, V. Forni, R. Voellinger, Yuanjia Wang, Allan Zuckoff, Melanie M. Wall, F. Stiefel, Satz Mengensatzproduktion, Druck Reinhardt Druck Basel, Druck Reinhardt Druck Basel
Journal: Psychotherapy and Psychosomatics (2012)
A Role of Matrix Metalloproteinase-8 in Atherosclerosis
Authors: Ross C. Laxton, Yanhua Hu, Johan Duchene, Feng Zhang, Zhongyi Zhang, Kit-Yi Leung, Qingzhong Xiao, Ramona S. Scotland, Conrad P. Hodgkinson, Katherine Smith, Johann Willeit, Carlos López-Otín, Iain A. Simpson, Stefan Kiechl, Amrita Ahluwalia, Qingbo Xu, Shu Ye
Journal: Circulation Research (2009)

Atherosclerotic lesions express matrix metalloproteinase (MMP)8, which possesses proteolytic activity on matrix proteins particularly fibrillar collagens and on nonmatrix proteins such as angiotensin (Ang) I.We studied whether MMP8 plays a role in atherogenesis.In atherosclerosis-prone apolipoprotein E-deficient mice, inactivating MMP8 resulted in a substantial reduction in atherosclerotic lesion formation. Immunohistochemical examinations showed that atherosclerotic lesions in MMP8-deficient mice had significantly fewer macrophages but increased collagen content. In line with results of in vitro assays showing that Ang I cleavage by MMP8 generated Ang II, MMP8 knockout mice had lower Ang II levels and lower blood pressure. In addition, we found that products of Ang I cleavage by MMP8 increased vascular cell adhesion molecule (VCAM)-1 expression and that MMP8-deficient mice had reduced VCAM-1 expression in atherosclerotic lesions. Intravital microscopy analysis showed that leukocyte rolling and adhesion on vascular endothelium was reduced in MMP8 knockout mice. Furthermore, we detected an association between MMP8 gene variation and extent of coronary atherosclerosis in patients with coronary artery disease. A relationship among MMP8 gene variation, plasma VCAM-1 level, and atherosclerosis progression was also observed in a population-based, prospective study.These results indicate that MMP8 is an important player in atherosclerosis.
Radiation and ATM inhibition: the heart of the matter
Authors: Ester M. Hammond, Ruth J. Muschel
Journal: Journal of Clinical Investigation (2014)

Numerous in vitro studies have shown that human cell lines lacking functional ATM are extremely radiosensitive. In this issue, Moding et al. demonstrate using a murine model of sarcoma that deletion of the Atm gene has much less of a radiosensitizing effect on normal cardiac endothelia than on rapidly proliferating tumor endothelia. This work confounds our assumptions about the generality of the role of ATM in radiation sensitivity and the potential use of ATM inhibitors as radiosensitizers.
HYDROPHOBIA EPIDEMICS.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Single-cell multi-omic approaches define common molecular and cellular signals of dominant antigen-driven cells at the site of drug-induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) tissue damage
Authors: Andrew Gibson, Yueran Li, Michael Thorne, Ramesh Ram, Amy Palubinsky, Phuti Choshi, Mireille Porter, Jason Trubiano, Pooja Deshpande, Abha Chopra, Shay Leary, Rama Gangula, Katie White, Mark Pilkington, Katherine Konvinse, Chuang-Wei Wang, Ren-You Pan, Shuen-Iu Hung, Wen-Hung Chung, Jonny Peter, Simon Mallal, Elizabeth Phillips
Journal: Journal of Allergy and Clinical Immunology (2022)
Human skin-resident host T cells can persist long term after allogeneic stem cell transplantation and maintain recirculation potential
Authors: Gustavo P. de Almeida, Peter Lichtner, Gertrud Eckstein, Tonio Brinkschmidt, Chang-Feng Chu, Shan Sun, Julian Reinhard, Sophia C. Mädler, Markus Kloeppel, Mareike Verbeek, Christina E. Zielinski
Journal: Science Immunology (2022)

Tissue-resident memory T cells (T RM ) have recently emerged as crucial cellular players for host defense in a wide variety of tissues and barrier sites. Insights into the maintenance and regulatory checkpoints of human T RM cells remain scarce, especially due to the difficulties associated with tracking T cells through time and space in humans. We therefore sought to identify and characterize skin-resident T cells in humans defined by their long-term in situ lodgment. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) preceded by myeloablative chemotherapy unmasked long-term sequestration of host T cell subsets in human skin despite complete donor T cell chimerism in the blood. Single-cell chimerism analysis paired with single-cell transcriptional profiling comprehensively characterized these bona fide long-term skin-resident T cells and revealed differential tissue maintenance for distinct T cell subsets, specific T RM cell markers such as galectin-3, but also tissue exit potential with retention of the transcriptomic T RM cell identity. Analysis of 26 allo-HSCT patients revealed profound interindividual variation in the tissue maintenance of host skin T cells. The long-term persistence of host skin T cells in a subset of these patients did not correlate with the development of chronic GvHD. Our data exemplify the power of exploiting a clinical situation as a proof of concept for the existence of bona fide human skin T RM cells and reveal long-term persistence of host T cells in a peripheral tissue but not in the circulation or bone marrow in a subset of allo-HSCT patients.
预测儿童期特应性皮炎的长期病程
Journal: British Journal of Dermatology (2022)

Journal Article 预测儿童期特应性皮炎的长期病程 Get access British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Page e105, https://doi.org/10.1111/bjd.20933 Published: 01 February 2022
Will to win as a psychological differential to play and triumph among male runners, jumpers and throwers
Authors: Vikram Singh, T Onima Reddy
Journal: British Journal of Sports Medicine (2010)

The purpose of the study was to compare will to win as a psychological differential to play and triumph among male runners, jumpers and throwers. For the purpose of the study, 60 male athletes (15 short distance runners, 15 long distance runners, 15 jumpers and 15 throwers) were randomly selected from 10th National Junior Federation Cup Athletic Championship 2010 held at Visakhapatnam as the subjects of the study. The variable selected for the purpose of this study was: will to win. Will to win was assessed by the total scores in Will to Win Questionnaire constructed and standardised by Prof Anand Kumar Shrivastava and Prem Shankar Shukla. With the help of the questionnaire related to will to win as a psychological variable necessary data were collected. Data were collected with regard to will to win variable from 60 male athletes in 10th National Junior Federation Cup Athletic Championship 2010 held at Visakhapatnam. The data was analysed by applying descriptive statistic that is, mean, SD, SE and range and analysis of variance. The level of significance was set at 0.05. The findings of the study in relation to will to win showed significant difference among long distance runners in comparison to short distance runners, jumpers and throwers. On the basis of the findings of the study, the following conclusions are drawn: long distance runner possessed high will to win in comparison to short distance runners, jumpers and throwers because will to win is defined as the intensity of the desire to defeat an opponent or to exceed some performance standard in a given sports. The sequence of will to win among athletes was long distance runners, throwers, short distance runners and jumpers.
Erratum
Authors: Giovanni A. Fava, G. Ba, E. Fava, I. Carta, M. Clerici, S. Albonetti, R. Papa, G. Penati, G. Invernizzi, James D.A. Parker, Graeme J. Taylor, Michael Bagby, Robert Kellner, Juan Hernandez, Dorothy Pathak, Töres Theorell, Jenifer Wilson-Barnett, L.G. Sobrinho, J.M. Almeida-Costa
Journal: Psychotherapy and Psychosomatics (1992)
Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study
Authors: Shuang Hao, Emelie Heintz, Ellinor Östensson, Andrea Discacciati, Fredrik Jäderling, Henrik Grönberg, Martin Eklund, Tobias Nordström, Mark S. Clements
Journal: European Urology (2022)

Stockholm3 is a risk model that combines the prostate-specific antigen (PSA) test, other plasma protein biomarkers, single nucleotide polymorphisms, and clinical variables. The STHLM3-MRI study (NCT03377881) found that the Stockholm3 test with magnetic resonance imaging (MRI) and combined targeted and systematic biopsies maintained the sensitivity for clinically significant cancers, and reduced the number of benign biopsies and clinically insignificant cancers.To assess the cost-effectiveness of MRI-based screening for prostate cancer using either Stockholm3 as a reflex test or PSA alone.A cost-utility analysis was performed from a lifetime societal perspective using a microsimulation model for men aged 55-69 yr in Sweden. Test characteristics were estimated from the STHLM3-MRI study.No screening and three quadrennial screening strategies, including either PSA ≥3 ng/ml or Stockholm3 with reflex test thresholds of PSA ≥1.5 or 2 ng/ml as criteria for referral to MRI, were performed, and those who were MRI positive had combined targeted and systematic biopsies.Predictions included the number of tests, cancer incidence and mortality, costs, and quality-adjusted life-years. Uncertainties in key parameters were assessed using sensitivity analyses.Compared with no screening, the screening strategies were predicted to reduce prostate cancer deaths by 7-9% across a lifetime. The use of Stockholm3 with PSA ≥2 ng/ml resulted in a 60% reduction in MRI compared with screening using PSA. This Stockholm3 strategy was cost-effective with a probability of 70% at a cost-effectiveness threshold of €47 218 (500 000 Swedish Kronor). As a potential limitation, the economic perspective was specific to Sweden.Screening with the Stockholm3 test at a reflex threshold of PSA ≥2 ng/ml and MRI was predicted to be cost-effective in Sweden.The Stockholm3 test with image-based screening may reduce screening-related harms and costs, while maintaining the health benefits from early detection of prostate cancer.
Decoding Cancer Biology One Cell at a Time
Authors: L. Nicolas Gonzalez Castro, Itay Tirosh, Mario L. Suvà
Journal: Cancer Discovery (2021)

Abstract Human tumors are composed of diverse malignant and nonmalignant cells, generating a complex ecosystem that governs tumor biology and response to treatments. Recent technological advances have enabled the characterization of tumors at single-cell resolution, providing a compelling strategy to dissect their intricate biology. Here we describe recent developments in single-cell expression profiling and the studies applying them in clinical settings. We highlight some of the powerful insights gleaned from these studies for tumor classification, stem cell programs, tumor microenvironment, metastasis, and response to targeted and immune therapies. Significance: Intratumor heterogeneity (ITH) has been a major barrier to our understanding of cancer. Single-cell genomics is leading a revolution in our ability to systematically dissect ITH. In this review, we focus on single-cell expression profiling and lessons learned in key aspects of human tumor biology.
Longitudinal Adherence to Inhaled Corticosteroids in Pediatric Patients with Difficult to Control Asthma
Authors: Rachelle Ramsey, Theresa Guilbert, Kristina Keidel, John Kroner, Amy Noser, Jocelyn Biagini, Kristi Curtsinger, Sandy Durrani, Mariana Stevens, Lisa Martin, Valentina Pilipenka, Carolyn Kersmar, Kevin Hommel, Gurjit Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2022)
Efficacy and Safety of Gene Therapy for β-Thalassemia
Authors: Emmanuel Payen
Journal: New England Journal of Medicine (2022)

β-Thalassemia results from insufficient production of the hemoglobin subunit β-globin (β+) or from the absence of β-globin (β0). Low levels of adult hemoglobin (HbA, or α2β2) are exacerbated by excess free α-globin chains in erythroid cells, leading to dyserythropoiesis and shortening red-cell survival. Patients with transfusion-dependent β-thalassemia, the most severe clinical form of this disorder, receive repeated red-cell transfusions in order to prevent severe anemia and increase survival. However, iron overload caused by transfusions often leads to dysfunction in the heart, endocrine glands, and liver. Allogeneic hematopoietic stem-cell transplantation, which is routinely used in children with β-thalassemia, can increase overall . . .
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation31This document was approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001.32When citing this document, the American College of Cardiology, the American Heart Association, and the …
Authors: Valentin Fuster, Lars E. Rydén, Richard W. Asinger, David S. Cannom, Harry J. Crijns, Robert L. Frye, Jonathan L. Halperin, G.Neal Kay, Werner W. Klein, Samuel Lévy, Robert L. McNamara, Eric N. Prystowsky, L.Samuel Wann, D.George Wyse, Raymond J. Gibbons, Elliott M. Antman, Joseph S. Alpert, David P. Faxon, Valentin Fuster, Gabriel Gregoratos, Loren F. Hiratzka, Alice K. Jacobs, Richard O. Russell, Sidney C. Smith, Werner W. Klein, Angeles Alonso-Garcia, Carina Blomström-Lundqvist, Guy De Backer, Marcus Flather, Jaromir Hradec, Ali Oto, Alexander Parkhomenko, Sigmund Silber, Adam Torbicki
Journal: Journal of the American College of Cardiology (2001)
Improve Eczema/Asthma Research Study Enrollment and Retention Using Engaging, Participant Co-designed Graphic-Style Stories
Authors: Melinda Butsch Kovacic, Carissa Beckham, Susan Gertz, Shereen Elshaer, Eshika Kohli, Jocelyn Biagini, Gurjit Khurana Hershey, Susan Hershberger
Journal: Journal of Allergy and Clinical Immunology (2022)
Endothelial PPARδ facilitates the post-ischemic vascular repair through interaction with HIF1α
Authors: Yalan Wu, Xiaolong Tang, Sharen Lee, Huiling Hong, Xiaoyun Cao, Chi Wai Lau, Baohua Liu, Ajay Chawla, Ronald Ching Wan Ma, Yu Huang, Kathy O Lui, Xiao Yu Tian
Journal: Theranostics (2022)

Rationale: Restoration of vascular perfusion in peripheral arterial disease involves a combination of neovessel formation and the functional restoration of vascular endothelium.Previous studies indicated that ligand-dependent PPARδ activation enhances angiogenesis.However, how PPARδ is triggered by hypoxia and its downstream effects during post-ischemic vascular repair was not well understood.Methods: We induced experimental hindlimb ischemia in endothelial cell selective Ppard knockout induced by Cdh5-Cre mediated deletion of floxed Ppard allele in mice and their wild type control and observed blood perfusion, capillary density, vascular relaxation, and vascular leakage.Results: Deletion of endothelial Ppard delayed perfusion recovery and tissue repair, accompanied by delayed post-ischemic angiogenesis, impaired restoration of vascular integrity, more vascular leakage and enhanced inflammatory responses.At the molecular level, hypoxia upregulated and activated PPARδ in endothelial cells, whereas PPARδ reciprocally stabilized HIF1α protein to prevent its ubiquitin-mediated degradation.PPARδ directly bound to the oxygen-dependent degradation domain of HIF1α at the ligand-dependent domain of PPARδ.Importantly, this HIF1α-PPARδ interaction was independent of PPARδ ligand.Adeno-associated virus mediated endothelium-targeted overexpression of stable HIF1α in vivo improved perfusion recovery, suppressed vascular inflammation, and enhanced vascular repair, to counteract with the effect of Ppard knockout after hindlimb ischemia in mice.Conclusions: In summary, hypoxia-induced, ligand-independent activation of PPARδ in ECs stabilizes HIF1α and serves as a critical regulator for HIF1α activation to facilitate the post-ischemic restoration of vascular homeostasis.
Homologous and Heterologous Covid-19 Booster Vaccinations
Authors: Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck, Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Christine M. Posavad, Janet I. Archer, Sonja Crandon, Seema U. Nayak, Daniel Szydlo, Jillian A. Zemanek, Clara P. Dominguez Islas, Elizabeth R. Brown, Mehul S. Suthar, M. Juliana McElrath, Adrian B. McDermott, Sarah E. O’Connell, David C. Montefiori, Amanda Eaton, Kathleen M. Neuzil, David S. Stephens, Paul C. Roberts, John H. Beigel
Journal: New England Journal of Medicine (2022)

Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients.In this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.Of the 458 participants who were enrolled in the trial, 154 received mRNA-1273, 150 received Ad26.COV2.S, and 153 received BNT162b2 as booster vaccines; 1 participant did not receive the assigned vaccine. Reactogenicity was similar to that reported for the primary series. More than half the recipients reported having injection-site pain, malaise, headache, or myalgia. For all combinations, antibody neutralizing titers against a SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73, and binding titers increased by a factor of 5 to 55. Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73. Spike-specific T-cell responses increased in all but the homologous Ad26.COV2.S-boosted subgroup. CD8+ T-cell levels were more durable in the Ad26.COV2.S-primed recipients, and heterologous boosting with the Ad26.COV2.S vaccine substantially increased spike-specific CD8+ T cells in the mRNA vaccine recipients.Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by the National Institute of Allergy and Infectious Diseases; DMID 21-0012 ClinicalTrials.gov number, NCT04889209.).